ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
-0.04 (-0.32%)
After Hours: 12.60 -0.01 (-0.08%)
Nov 24, 6:42PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.38 - 12.78
52 week 3.42 - 14.93
Open 12.43
Vol / Avg. 1.45M/2.82M
Mkt cap 1.63B
P/E     -
Div/yield     -
EPS -1.04
Shares 130.89M
Beta 1.57
Inst. own 49%
Nov 2, 2015
Q3 2015 ZIOPHARM Oncology Inc Earnings Release
Sep 10, 2015
ZIOPHARM Oncology Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -972.18% -2314.71%
Operating margin -971.96% -3168.17%
EBITD margin - -3134.52%
Return on average assets -49.01% -54.33%
Return on average equity -71.35% -76.37%
Employees 27 -
CDP Score - -


One First Avenue Parris Building 34 Navy Yard Plaza
BOSTON, MA 02129
United States - Map
+1-646-2140700 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company's clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Officers and directors

Laurence James Neil Cooper M.D., Ph.D. Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Kevin G. Lafond CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 58
Bio & Compensation  - Reuters
Caesar J. Belbel Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
Age: 55
Bio & Compensation  - Reuters
Murray Brennan Non-Executive Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 61
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 76
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 74
Bio & Compensation  - Reuters
Timothy McInerney Independent Director
Age: 54
Bio & Compensation  - Reuters